Boys Arnold & Co. Inc. cut its position in shares of Celgene Co. (NASDAQ:CELG) by 14.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,196 shares of the biopharmaceutical company’s stock after selling 1,429 shares during the quarter. Boys Arnold & Co. Inc.’s holdings in Celgene were worth $512,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in CELG. HL Financial Services LLC boosted its position in shares of Celgene by 20.5% in the third quarter. HL Financial Services LLC now owns 4,213 shares of the biopharmaceutical company’s stock worth $377,000 after buying an additional 717 shares during the period. FMR LLC boosted its position in shares of Celgene by 26.0% in the third quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock worth $919,890,000 after buying an additional 2,119,257 shares during the period. ING Groep NV boosted its position in shares of Celgene by 116.3% in the third quarter. ING Groep NV now owns 203,229 shares of the biopharmaceutical company’s stock worth $18,187,000 after buying an additional 109,292 shares during the period. Morgan Stanley boosted its position in shares of Celgene by 20.4% in the third quarter. Morgan Stanley now owns 3,236,323 shares of the biopharmaceutical company’s stock worth $289,620,000 after buying an additional 549,404 shares during the period. Finally, IFM Investors Pty Ltd boosted its position in shares of Celgene by 12.3% in the third quarter. IFM Investors Pty Ltd now owns 38,302 shares of the biopharmaceutical company’s stock worth $3,428,000 after buying an additional 4,193 shares during the period. Institutional investors own 72.71% of the company’s stock.
A number of research analysts recently commented on CELG shares. UBS Group set a $94.00 price target on Celgene and gave the company a “buy” rating in a report on Saturday, October 27th. Jefferies Financial Group downgraded Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a report on Friday, February 1st. Wells Fargo & Co reduced their price target on Celgene from $90.00 to $84.00 and set a “market perform” rating for the company in a report on Thursday, January 3rd. Morgan Stanley reduced their price target on Celgene from $93.00 to $88.00 and set an “equal weight” rating for the company in a report on Wednesday, December 19th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $100.00 price target on shares of Celgene in a report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $109.29.
Shares of NASDAQ CELG opened at $87.91 on Friday. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $97.43. The company has a market cap of $61.32 billion, a price-to-earnings ratio of 11.55, a PEG ratio of 0.41 and a beta of 1.72. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a return on equity of 125.35% and a net margin of 26.48%. The firm had revenue of $4.04 billion for the quarter, compared to analysts’ expectations of $3.98 billion. During the same quarter in the prior year, the firm posted $2.00 earnings per share. As a group, equities research analysts predict that Celgene Co. will post 10.01 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was posted by Macon Daily and is the property of of Macon Daily. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://macondaily.com/2019/02/09/celgene-co-celg-shares-sold-by-boys-arnold-co-inc.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: Capital gains and your 401(k) or IRA
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.